Results 31 to 40 of about 1,265,615 (248)

Immune-Checkpoint Blockade Therapy in Lymphoma

, 2020
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on ...
Yosuke Minami, Nobuhiko Yamauchi, SungGi Chi, Ayumi Kuzume   +3 more
core   +1 more source

Smoldering myocarditis following immune checkpoint blockade [PDF]

, 2017
Background Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of less than 1%.
Litovsky, Silvio, Silvio H. Litovsky, Westbrook, Brian, Moslehi, Javid, Svetlana B. McKee, Douglas B. Johnson, Norwood, Timothy, Conry, Robert, Javid J. Moslehi, Brian C. Westbrook, Nina L. Terry, Johnson, Douglas, Alan S. Gertler, McKee, Svetlana, Terry, Nina, Timothy G. Norwood, Gertler, Alan, Robert M. Conry   +17 more
core   +1 more source

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

Frontiers in Oncology, 2022
Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to
Yiming Wei, Zhaoming Li
doaj   +1 more source

Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors [PDF]

Journal of Immunotherapy and Precision Oncology, 2020
A major breakthrough in cancer treatment was ushered in by the development of immune checkpoint blockade therapy such as anti-CTLA4 antibody and anti-PD-1 and anti-programmed cell death-ligand 1 antibodies that are now approved for use in an increasing ...
Kathrina L. Marcelo-Lewis, Shhyam Moorthy, Ecaterina Ileana-Dumbrava   +2 more
doaj   +1 more source

Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions [PDF]

, 2022
Immunotherapies seek to unleash the immune system against cancer cells. While a variety of immunotherapies exist, one of the most commonly used is immune checkpoint blockade, which refers to the use of antibodies to interfere with immunosuppressive ...
Haddad, Alexander F., Gill, Sabraj, Aghi, Manish K., Alexander F. Haddad, Young, Jacob S, Manish K. Aghi, Jacob S. Young, Aghi, Manish K, Sabraj Gill, Young, Jacob S., Haddad, Alexander F   +10 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm

Molecular Oncology
Immune checkpoint blockade has emerged as a potent new tool in the war on cancer. However, only a subset of cancer patients benefit from this therapeutic modality, sparking a search for combination therapies to increase the fraction of responding ...
Mary C. Clark, Rongze Olivia Lu, Winson S. Ho, Matheus Henrique Dias, René Bernards, Stephen J. Forman   +5 more
doaj   +1 more source

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer

Open Biology, 2021
Radiation has been a pillar of cancer therapy for decades. The effects of radiation on the anti-tumour immune response are variable across studies and have not been explicitly defined in poorly immunogenic tumour types.
Courtney T. Stump, Kevin Roehle, Nataly Manjarrez Orduno, Stephanie K. Dougan   +3 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source